TNSN96023A1 - Nouvelle formulation pharmaceutique - Google Patents

Nouvelle formulation pharmaceutique

Info

Publication number
TNSN96023A1
TNSN96023A1 TNTNSN96023A TNSN96023A TNSN96023A1 TN SN96023 A1 TNSN96023 A1 TN SN96023A1 TN TNSN96023 A TNTNSN96023 A TN TNSN96023A TN SN96023 A TNSN96023 A TN SN96023A TN SN96023 A1 TNSN96023 A1 TN SN96023A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical formulation
new pharmaceutical
prophylactic
pharmaceutical composition
relates
Prior art date
Application number
TNTNSN96023A
Other languages
English (en)
Inventor
Nils-Erik Anders Carlsson
Johan Georg Harmenberg
Bengt Goran Herslof
Ann Harriet Margareta Kristofferson
Karl Stefan Lundquist
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of TNSN96023A1 publication Critical patent/TNSN96023A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION SE RAPPORTE A UNE COMPOSITION PHARMACEUTIQUE POUR ADMINISTRATION TOPIQUE COMPRENANT UNE COMBINAISON DE FOSCARNET ET D'UN GLUCOCORTICOIDE ANTI-INFLAMMATOIRE, AJOUTES A UN VECTEUR REALISE A PARTIR DE GALACTOLIPIDES ET D'N SOLVANT POLAIRE. LA COMPOSITION PHARMACEUTIQUE PEUT ETRE UTILISEE DANS UN TRAITEMENT PROPHYLACTIQUE ET/ OU CURATIF D'INFECTION A L'HERPESVIRUS CHEZ LES MAMMIFERES Y COMPRIS L'HOMME. L'INVENTION SE RAPPORTE EGALEMENT A L'USAGE DE LA DITE COMPOSITION DANS LA FABRICATION D'UN MEDICAMENT POUR LE DIT TRAITEMENT PROPHYLACTIQUE OU CURATIF
TNTNSN96023A 1995-02-06 1996-02-05 Nouvelle formulation pharmaceutique TNSN96023A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9500112 1995-02-06

Publications (1)

Publication Number Publication Date
TNSN96023A1 true TNSN96023A1 (fr) 2005-03-15

Family

ID=20396817

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN96023A TNSN96023A1 (fr) 1995-02-06 1996-02-05 Nouvelle formulation pharmaceutique

Country Status (18)

Country Link
US (1) US6068860A (fr)
EP (1) EP0809501A1 (fr)
JP (1) JPH11509515A (fr)
KR (1) KR19980701958A (fr)
AR (1) AR002274A1 (fr)
AU (1) AU715212B2 (fr)
CA (1) CA2211409A1 (fr)
DZ (1) DZ1965A1 (fr)
FI (1) FI973230A (fr)
HR (1) HRP960033A2 (fr)
IL (1) IL116910A0 (fr)
MA (1) MA23799A1 (fr)
NO (1) NO973611L (fr)
NZ (1) NZ301406A (fr)
TN (1) TNSN96023A1 (fr)
WO (1) WO1996024359A1 (fr)
YU (1) YU7196A (fr)
ZA (1) ZA96526B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438585B (en) * 1995-02-06 2001-06-07 Astra Ab Pharmaceutical compositions for topical administration for prophylaxis and/or treatment of herpesvirus infections
FR2814071A1 (fr) * 2000-09-21 2002-03-22 Oreal Composition a base de glycoglyceride et ses utilisations notamment cosmetiques
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CN104117066B (zh) * 2014-07-16 2016-03-02 陈凌 外敷用抗甲状腺软膏的制备方法
WO2016068849A1 (fr) 2014-10-27 2016-05-06 Hewlett-Packard Development Company, L.P. Dispositif d'impression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2964024D1 (en) * 1978-10-02 1982-12-16 Procter & Gamble Liposomes for drug delivery and composition containing a liposome drug system
US4512978A (en) * 1980-01-24 1985-04-23 Inwood Louis R Dermatological composition useful in the treatment of psoriasis
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0249561B1 (fr) * 1986-06-12 1992-05-13 The Liposome Company, Inc. Compositions utilisant des médicaments anti-inflammatoires non-stéroides encapsulés dans des liposomes
WO1989005152A1 (fr) * 1987-12-09 1989-06-15 The Regents Of The University Of California Procede et composition anti-virale encapsulee dans des liposomes
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
GB9315755D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized formulation

Also Published As

Publication number Publication date
FI973230A0 (fi) 1997-08-05
KR19980701958A (ko) 1998-06-25
FI973230A (fi) 1997-08-05
AU4682096A (en) 1996-08-27
WO1996024359A1 (fr) 1996-08-15
NZ301406A (en) 1999-01-28
MA23799A1 (fr) 1996-10-01
ZA96526B (en) 1996-08-06
AR002274A1 (es) 1998-03-11
AU715212B2 (en) 2000-01-20
YU7196A (sh) 1998-09-18
EP0809501A1 (fr) 1997-12-03
CA2211409A1 (fr) 1996-08-15
HRP960033A2 (en) 1997-10-31
US6068860A (en) 2000-05-30
IL116910A0 (en) 1996-09-12
DZ1965A1 (fr) 2002-07-17
NO973611D0 (no) 1997-08-05
NO973611L (no) 1997-09-26
JPH11509515A (ja) 1999-08-24

Similar Documents

Publication Publication Date Title
TNSN96024A1 (fr) Nouvelle combinaison pharmaceutique
Kaplan et al. Antipsoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis
MA25284A1 (fr) Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.
FR2378523A1 (fr) Medicament pour le traitement de l'acne
BE901667A (fr) Composition analgesique et anti-inflammatoire a base de diphenhydramine, leur preparation et leur utilisation.
CA2175643A1 (fr) Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
TNSN98229A1 (fr) Formulation pharmaceutique orale a liberation prolongee
MX9102209A (es) Derivados de acido hidroxamico y n-hidroxiurea novedosos y su uso.
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
FR2755852B1 (fr) Utilisation d'un alkylether de glycerol dans une composition cosmetique et/ou dermatologique comme actif pour le traitement de la seborrhee et de l'acne
CA2246289A1 (fr) Nouvelles associations de principes actifs contenant du clopidogrel et un antithrombotique
US4256763A (en) Treatment of herpes simplex infections and acne
HK1002552A1 (en) Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions
BE900564A (fr) Composition pharmaceutique pour le traitement d'arteriopathies peripheriques.
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
TNSN96023A1 (fr) Nouvelle formulation pharmaceutique
FR2469925A1 (fr) Utilisation de la b-cyclodextrine comme agent anti-acne
EP0532705A1 (fr) Derives quinoleinyle-benzoheterobicycliques utilises comme antagonistes de leucotriene d 4?
CA2165520A1 (fr) Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
FR2754177B1 (fr) Microspheres pharmaceutiques d'acide valproique pour administration orale
CA2235038A1 (fr) Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
EP0402933B2 (fr) Utilisation du gel humide de sucralfate comme véhicule pour médicaments à activité topique et pour des produits cosmétiques
CA2172779A1 (fr) Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
CA2172778A1 (fr) Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
BE902796A (fr) Ester d'acetyl carnitine, sa preparation et son utilisation.